Emerging biomarkers and new therapeutic breakthroughs in MASLD and MASLD-HCC

A new review published in Science Bulletin underscores the escalating global burden of MASLD, which now affects roughly 30 % of the world’s population and can progress to metabolic dysfunction‑associated steatohepatitis (MASH), fibrosis, cirrhosis and ultimately hepatocellular carcinoma (HCC). The authors emphasize that early detection and multifaceted treatment are essential to cope with the rising incidence of MASLD and MASLD-HCC.

Advancement in Non‑Invasive Biomarkers

A critical step toward improving diagnostic efficiency involves replacing invasive liver biopsy, the long-considered gold standard for diagnosis, with reliable non-invasive alternatives. The authors detail a new generation of non-invasive biomarkers that promise enhanced diagnostic precision and earlier disease detection. Multi‑omic panels that combine genetic, metabolic and microbiome makers have shown high diagnostic accuracy, outperforming traditional MASH and fibrosis assessments. Gut‑microbiome signatures are gaining attention as diagnostic tools, with specific bacterial species and their derived metabolites distinguishing disease stages and predicting at-risk patients. Molecular markers such as microRNAs and serum proteins have demonstrated superior performance over the classic alpha‑fetoprotein test for early HCC detection. The integration of these multi-omic biomarkers aims to capture the full heterogeneity of the disease, enabling more precise risk stratification and monitoring of treatment response.

Therapeutic Advances

On the therapeutic front, the recent FDA approval of resmetirom and semaglutide marks a pivotal milestone, providing the first pharmacological options specifically for patients with MASH and moderate-to-advanced fibrosis. Along with a robust pipeline of investigational drugs now in phase 3 clinical trials, including agents that target various metabolic pathways to reduce liver fat, resolve inflammation, and reverse fibrosis. However, treatment for MASLD-HCC remains a challenge, as preclinical and clinical evidence suggest that these patients often exhibit a diminished response to standard immunotherapies, such as immune checkpoint inhibitors. This resistance is attributed to the unique, immunosuppressive tumor microenvironment created by the underlying metabolic dysfunction, underscoring the need for combination regimens that can overcome these specific immunological hurdles.

Challenges and Future Directions in Clinical Translation of Newly Developed Biomarkers

Despite these promising findings, the authors underscore significant barriers hindering the clinical translation of these innovations. A primary challenge is the lack of sufficient analytical and clinical validation cohorts for biomarkers across diverse, multi-ethnic populations, which limits their generalizability. The inherent heterogeneity of MASLD itself complicates the development of universally applicable diagnostic cutoffs. To overcome these obstacles, the review calls for large-scale, prospective longitudinal studies to confirm the prognostic value and cost-effectiveness of new tools. Furthermore, it advocates for the standardization of analytical procedures, the establishment of clear regulatory frameworks, and the seamless integration of non-invasive biomarkers into electronic health records to support systematic screening and monitoring in real-world settings. Such coordinated efforts are essential to ensure that novel diagnostics and therapies are not only effective but also accessible and reliable for routine clinical use, paving the way for a new era of personalized management for patients with MASLD.

---

---